NZ535531A - Compound and use in treatment - Google Patents

Compound and use in treatment

Info

Publication number
NZ535531A
NZ535531A NZ535531A NZ53553104A NZ535531A NZ 535531 A NZ535531 A NZ 535531A NZ 535531 A NZ535531 A NZ 535531A NZ 53553104 A NZ53553104 A NZ 53553104A NZ 535531 A NZ535531 A NZ 535531A
Authority
NZ
New Zealand
Prior art keywords
bph
preservatives
compound
alpha
treatment
Prior art date
Application number
NZ535531A
Other languages
English (en)
Inventor
Luciano Adorini
Enrico Colli
Original Assignee
Bioxell Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322395A external-priority patent/GB0322395D0/en
Priority claimed from GB0325598A external-priority patent/GB2407499B/en
Priority claimed from GB0416876A external-priority patent/GB0416876D0/en
Application filed by Bioxell Spa filed Critical Bioxell Spa
Publication of NZ535531A publication Critical patent/NZ535531A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NZ535531A 2003-09-24 2004-09-23 Compound and use in treatment NZ535531A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322395A GB0322395D0 (en) 2003-09-24 2003-09-24 Methods for treating bladder dysfunction and related compounds and compositions
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
GB0416876A GB0416876D0 (en) 2004-07-29 2004-07-29 Compound and use in treatment

Publications (1)

Publication Number Publication Date
NZ535531A true NZ535531A (en) 2006-03-31

Family

ID=34229055

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ535531A NZ535531A (en) 2003-09-24 2004-09-23 Compound and use in treatment

Country Status (11)

Country Link
EP (1) EP1673096A1 (fr)
JP (2) JP2007506699A (fr)
CN (1) CN100488511C (fr)
BE (1) BE1016292A3 (fr)
BR (1) BRPI0404050A (fr)
CH (1) CH698144B1 (fr)
EA (1) EA010240B1 (fr)
FR (1) FR2859910B1 (fr)
NL (1) NL1027109C2 (fr)
NZ (1) NZ535531A (fr)
WO (1) WO2005027923A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006038611A1 (ja) * 2004-10-05 2008-05-15 キッセイ薬品工業株式会社 下部尿路閉塞疾患に伴う蓄尿障害の予防及び／又は治療剤
SI1806136T1 (sl) * 2004-10-06 2012-03-30 Kissei Pharmaceutical Medicinski sestavek za preprečevanje prehoda na operativno zdravljenje prostatične hipertrofije
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US20120164240A1 (en) 2010-12-22 2012-06-28 Audino David Lawrence Enriched a. blitoides compositions and uses thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
FR3063906B1 (fr) * 2017-03-20 2025-12-12 Pf Medicament Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate
CN120960385A (zh) * 2025-08-01 2025-11-18 上海交通大学医学院附属第九人民医院 5α–还原酶降解分子及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
TW403735B (en) * 1995-11-22 2000-09-01 Hoffmann La Roche 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol
SG70009A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Vitamin d3 analogs
AU743514B2 (en) * 1997-05-16 2002-01-24 Women & Infants Hospital Cyclic ether vitamin D3 compounds, 1alpha (OH) 3-EPI-vitamin D3 compounds and uses thereof
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
US6255501B1 (en) * 1999-04-26 2001-07-03 Hoffman-La Roche Inc. Process for preparing antiosteoporotic agents
US8496960B2 (en) * 2001-10-23 2013-07-30 Purdue Pharma L.P. Terazosin transdermal device and methods
JP2005515996A (ja) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンｄ化合物を含む薬学的組成物

Also Published As

Publication number Publication date
HK1085373A1 (zh) 2006-08-25
FR2859910A1 (fr) 2005-03-25
CH698144B1 (fr) 2009-05-29
CN100488511C (zh) 2009-05-20
BRPI0404050A (pt) 2005-06-14
FR2859910B1 (fr) 2006-04-28
EA200401100A1 (ru) 2005-04-28
CN1615891A (zh) 2005-05-18
BE1016292A3 (nl) 2006-07-04
NL1027109A1 (nl) 2005-03-29
JP2009035559A (ja) 2009-02-19
EA010240B1 (ru) 2008-06-30
WO2005027923A1 (fr) 2005-03-31
JP2007506699A (ja) 2007-03-22
EP1673096A1 (fr) 2006-06-28
NL1027109C2 (nl) 2005-05-03

Similar Documents

Publication Publication Date Title
WO2003049702A8 (fr) Ligands de recepteur vanilloide et utilisation de ceux-ci dans des traitements
CA2238993A1 (fr) Procedes de traitement du cancer de la prostate avec des antagonistes de la luliberine
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
MXPA03007140A (es) Derivados de carbolina.
PE20011167A1 (es) Composiciones farmaceuticas que comprenden un antagonista del alfa-adrenoreceptor y un antagonista muscarinico para el tratamiento de hiperplasia prostatica benigna
DK1689724T3 (da) Quinazolinonforbindelser som anticancermidler
DE60327103D1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
MX2019010879A (es) Tratamiento de cancer.
WO2001024763A3 (fr) Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
WO2005016286A3 (fr) Modulateurs pyraziniques de recepteurs canabinoïdes
EP1212055A4 (fr) Composition neurotherapeutique et procede associe
CL2007002953A1 (es) Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
WO2005049000A3 (fr) Methodes et compositions pour le traitement des troubles du metabolisme
DE60334536D1 (de) Furylverbindungen
NZ535531A (en) Compound and use in treatment
ECSP024382A (es) Inhibidores de proteasa de serina
WO2003094921A3 (fr) Utilisation d'inhibiteurs de la transduction de signal induite par le recepteur egf dans le traitement de l'hyperplasie/hypertrophie benigne de la prostate
DE60216233D1 (en) Carbolinderivate
SG162763A1 (en) Helix 12 directed non-steroidal antiandrogens
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
AU2001266575A1 (en) Chemical compounds
HRP20050510A2 (en) Microbicide substances
DK1383516T3 (da) Indgivelse af et polysaccharid samtidig med et kemoterapeutisk middel til behandling af cancer
WO2022272036A9 (fr) Inhibiteurs de tead et leurs utilisations
WO2001062239A3 (fr) Nouvelles compositions et utilisations de composes de dictyostatine

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)